Structural elucidation of new urinary tamoxifen metabolites by liquid chromatography quadrupole time-of-flight mass spectrometry

被引:8
作者
Lu, Jianghai [1 ]
He, Chunji [1 ]
He, Genye [1 ]
Wang, Xiaobing [1 ]
Xu, Youxuan [1 ]
Wu, Yun [1 ]
Dong, Ying [1 ]
Ouyang, Gangfeng [2 ]
机构
[1] China Antidoping Agcy, Natl Antidoping Lab, Beijing 100029, Peoples R China
[2] Sun Yat Sen Univ, Sch Chem & Chem Engn, KLGHEI Environm & Energy Chem, Guangzhou 510275, Guangdong, Peoples R China
来源
JOURNAL OF MASS SPECTROMETRY | 2014年 / 49卷 / 07期
关键词
tamoxifen; new metabolites; doping control; human urine; liquid chromatography quadruple time-of-flight mass spectrometry; BREAST-CANCER; CYP2D6; GENOTYPE; ESTROGEN-RECEPTOR; PHASE-I; PHARMACOGENOMICS; PLASMA; IDENTIFICATION; INHIBITORS; ENZYMES; CELLS;
D O I
10.1002/jms.3375
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In this study, tamoxifen metabolic profiles were investigated carefully. Tamoxifen was administered to two healthy male volunteers and one female patient suffering from breast cancer. Urinary extracts were analyzed by liquid chromatography quadruple time-of-flight mass spectrometry using full scan and targeted MS/MS techniques with accurate mass measurement. Chromatographic peaks for potential metabolites were selected by using the theoretical [M+H](+) as precursor ion in full-scan experiment and m/z 72, 58 or 44 as characteristic product ions for N,N-dimethyl, N-desmethyl and N, N-didesmethyl metabolites in targeted MS/MS experiment, respectively. Tamoxifen and 37 metabolites were detected in extraction study samples. Chemical structures of seven unreported metabolites were elucidated particularly on the basis of fragmentation patterns observed for these metabolites. Several metabolic pathways containing mono- and di-hydroxylation, methoxylation, N-desmethylation, N,N-didesmethylation, oxidation and combinations were suggested. All the metabolites were detected in the urine samples up to 1 week. Copyright (C) 2014 John Wiley & Sons, Ltd.
引用
收藏
页码:570 / 578
页数:9
相关论文
共 26 条
[1]   Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment [J].
Borges, Silvana ;
Desta, Zeruesenay ;
Li, Lang ;
Skaar, Todd C. ;
Ward, Bryan A. ;
Nguyen, Anne ;
Jin, Yan ;
Storniolo, Anna Maria ;
Nikoloff, D. Michele ;
Wu, Lin ;
Hillman, Grant ;
Hayes, Daniel F. ;
Stearns, Vered ;
Flockhart, David A. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 80 (01) :61-74
[2]   The G protein-coupled receptor GPR30 mediates the proliferative and invasive effects induced by hydroxytamoxifen in endometrial cancer cells [J].
Du, Gui-Qiang ;
Zhou, Long ;
Chen, Xiao-Yue ;
Wan, Xiao-Ping ;
He, Yin-Yan .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2012, 420 (02) :343-349
[3]   Sulfation of 4-Hydroxy Toremifene: Individual Variability, Isoform Specificity, and Contribution to Toremifene Pharmacogenomics [J].
Edavana, Vineetha Koroth ;
Dhakal, Ishwori B. ;
Yu, Xinfeng ;
Williams, Suzanne ;
Kadlubar, Susan .
DRUG METABOLISM AND DISPOSITION, 2012, 40 (06) :1210-1215
[4]   Development of a Micellar electrokinetic capillary chromatography method for the determination of three drugs employed in the erectile dysfunction therapy [J].
Flores, JR ;
Nevado, JJB ;
Peñalvo, GC ;
Diez, NM .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 811 (02) :231-236
[5]   Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer [J].
Gallicchio, L ;
Lord, G ;
Tkaczuk, K ;
Danton, M ;
Lewis, LM ;
Lim, CK ;
Flaws, JA .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 85 (01) :89-97
[6]  
Grace K. P., 1993, J AM SOC MASS SPECTR, V4, P588
[7]   Pharmacogenomics of tamoxifen and aromatase inhibitors [J].
Ingle, James N. .
CANCER, 2008, 112 (03) :695-699
[8]   Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen [J].
Johnson, MD ;
Zuo, H ;
Lee, KH ;
Trebley, JP ;
Rae, JM ;
Weatherman, RV ;
Desta, Z ;
Flockhart, DA ;
Skaar, TC .
BREAST CANCER RESEARCH AND TREATMENT, 2004, 85 (02) :151-159
[9]  
Kisanga ER, 2005, ANTICANCER RES, V25, P4487
[10]   Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters [J].
Kiyotani, Kazuma ;
Mushiroda, Taisei ;
Nakamura, Yusuke ;
Zembutsu, Hitoshi .
DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (01) :122-131